



**National Institute for
Health and Clinical Excellence**

MidCity Place
71 High Holborn
London
WC1V 6NA

Tel: +44 (0)20 7067 5800

Fax: +44 (0)20 7067 5801
nice@nice.org.uk

www.nice.org.uk

Dear Consultee / Commentator

**Health Technology Appraisal
Use of tumour necrosis factor alpha (TNF a) inhibitors (adalimumab, and
infliximab [review]) for Crohn's disease**

As you know, the Appraisal Committee met on 22 October 2008 to consider the responses received from consultees and commentators on the Appraisal Consultation Document (ACD) for Crohn's disease - adalimumab, and infliximab.

After careful consideration, and in response to the points raised at the committee meeting, we have commissioned the Decision Support Unit (DSU) to carry out extra work and perform re-analysis of the evidence considered. The DSU specification is attached for your information.

We will not be consulting on the work produced by the DSU before the next Committee meeting (see also sections 4.5.2.10, 4.5.2.11 and 4.5.4.4 of our Guide to the Technology Appraisals Process - <http://www.nice.org.uk/niceMedia/pdf/TAP.pdf>).

Consequently the anticipated Final Appraisal Determination (FAD) has not been agreed by the Committee. There will be an extension in the timelines for this appraisal and discussion of the topic at the next Committee Meeting on 22nd January 2009.

We are disappointed not to be able to progress this appraisal as planned but hope you understand the need to ensure that the Appraisal Committee has a sufficient base of evidence to inform its judgements.

Yours sincerely

Meindert Boysen
Associate Director, Centre for Health Technology Evaluation

Attachment: DSU Specification